Anne Merewood PhD MPH IBCLC Associate Professor of Pediatrics, Boston University School of Medicine Consultant to the Rocky Mountain Tribal Leaders Council.

Slides:



Advertisements
Similar presentations
Background Infant mortality is defined by the CDC as the death of an infant less than one year old. This is a critical indicator of the well being of a.
Advertisements

Neonatal Abstinence Syndrome: Taking Care of Mom and Baby Heather Rodman, PharmD PGY-2 Pediatric Pharmacy Resident Peyton Manning Children’s Hospital St.
Effective Risk Management Strategies in Outpatient Methadone Treatment: Clinical Guidelines and Liability Prevention Curriculum Module 9 Special Populations.
Healthy Border 2010: History and Health Measures Sam Notzon National Center for Health Statistics.
Neonatal Abstinence Syndrome: A Family Centered Approach to Care Kelly Outlaw, M.S., CCLS.
Fact sheet Policies and Programs to Address Drug-Exposed Newborns The use or abuse of either illegal or prescription drugs during pregnancy can have serious.
Moms on Meds Substance Abuse During Pregnancy: Jennifer Anderson Maddron, M.D.
The Effects of Drug Use on a Developing Fetus. The first trimester of a pregnancy (first 3 months; typically from 17 days after conception to 70 days)
SUBSTANCE ABUSE The Drug-Exposed Infant
Kelly Geraghty, Tracy James, Kristen Lintjer,
“Association of OPRM1 and COMT Single Nucleotide Polymorphisms with Hospital Length of Hospital Stay and Treatment of Neonatal Abstinence Syndrome” E Wachman,
V.Sideri, C.Vliora, A.Daskalaki, P.Mexi-Bourna, K.Kleanthous, M.Soulioti, G. Kyrkou, N.Bournas, V.Papaevangelou 3 rd Pediatric Clinic of the University.
Childhood Development Affected by Prenatal Drug Abuse Milene Francis Psychology 1100 April, 2014.
Education Guide for Parents and Caregivers. Neonatal Abstinence Syndrome (NAS) NAS may present in a baby who is exposed to medication taken by the mother.
Intergenerational impacts of maternal mortality related to HIV in South Africa L. Knight1 and A.E. Yamin2 1. School of Public Health, University of Western.
Chapter Objectives Define maternal, infant, and child health.
Women, Pregnancy and Substance Use Dependence Maternal and Child Health Conference 22 nd February 2013 Theresa Lynch Manager – Women’s Alcohol and Drug.
Nutrition Framing Maternal & Infant Nutrition.
Why are drugs so hard to quit?. Addiction: Being enslaved to a habit or practice or something that is psychologically or physically habit forming (to.
1 Adolescent Mental Health: Key Data Indicators Gwendolyn J. Adam, Ph.D., L.C.S.W. Assistant Professor - Department of Pediatrics Section of Adolescent.
Copyright © 2008 Delmar. All rights reserved. Chapter 22 Maternal and Child Populations.
THE PREVENTION OF MOTHER TO CHILD TRANSMISSION of HIV (PMTCT)
Peripartum Depression Laura J. Miller, M.D. Women’s Mental Health Program University of Illinois at Chicago.
©2013 Children's Mercy. All Rights Reserved. 09/13 The Drug Exposed Neonate; Now What? Neonatal Abstinence Syndrome (NAS) Betsy Knappen APRN, BSN, Jodi.
Healthy Women, Healthy Babies Jeffrey Levi, PhD Executive Director Trust for America’s Health.
EFFECTIVE INTERVENTIONS FOR NEWBORNS WITH DRUG EXPOSURE AND THEIR FAMILIES Harolyn M.E. Belcher, M.D., M.H.S. Associate Professor of Pediatrics Johns Hopkins.
Introduction to Nursing Care of the Childbearing Family
Demographics. National Statistics  “America’s Children: Key National Indicators of Well- Being, 2009” Report:  In 2008, 73.9 million children 0-17 y/o.
Substance Exposed Newborns and their Families Dixie L. Morgese, BA, CAP, ICADC.
Breastfeeding Support and Promotion Joan Younger Meek, MD, FAAP AAP Section on Breastfeeding.
Current Trends In Identifying And Treating Newborns With Withdrawal Syndromes 6/24/2010.
Health Care of at Risk Aggregate: Low Income Pregnant Women Kelley Deaton College of Nursing University of Central Florida.
Module IV: Identification of Patients for Buprenorphine Treatment BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals.
Maternal Mental Health: Preventing & Mitigating Its Effects Robin C. Kopelman, M.D., M.P.H. University of Iowa Department of Psychiatry Women’s Wellness.
Demographics. Why focus on children & adolescents?  Unique population – especially this generation.  The first to understand terrorism as a domestic.
Crack Cocaine Many Voices One Vision 2007 By: Aaron Jones, MPH.
Treatment of Opioid Dependency in Pregnancy and Strategies to Reduce Neonatal Abstinence Syndrome.
Incorporating Preconception Health into MCH Services
J. KATE BURKHART, EXECUTIVE DIRECTOR Behavioral Health Needs of Children and Youth in Interior Alaska.
Patty Zetterberg, MSN, C-PNP Director, Clinical Operations Medical Practice Management East Tennessee Children’s Hospital Neonatal Abstinence Syndrome.
By: Nicole Stevens  A syndrome of drug withdrawal with non- specific signs and symptoms that may occur in babies following in-utero drug exposure. 
ANGELS Update Antidepressants in Pregnancy Linda L.M. Worley, MD, Associate Professor UAMS, Departments of Psychiatry & OB/GYN.
Neonatal Abstinence Syndrome
The Problem of Neonatal Abstinence Syndrome (NAS) Opiates and Pregnancy.
Addressing the drug affected infant population and tools to end destructive cycles  Amy Baumann- BSW- Safe Babies Healthy Families  Colleen Allen- MSW,
Abusing Drugs During Pregnancy is Child Abuse Hannah Magyar CP English 12 Mrs. Mahoney May 5, 2015.
Neonatal Abstinence Syndrome: Preserving the Infant-Maternal Bond Haneme Idrizi, MD, FAAP Assistant Professor of Pediatrics, University of Texas Health.
Neonatal Abstinence Syndrome
Montana Healthcare Foundation: Overview and Integrated Behavioral Health Initiative
Racial/Ethnic Disparities in Gestational Diabetes Mellitus in Oregon Monica Hunsberger, MPH, RD, PhD 1, Rebecca J. Donatelle, PhD 2, Kenneth D. Rosenberg,
Renaissance Prenatal Care Program TM. “Every Renaissance comes to the world with a cry, the cry of the human spirit to be free” -Anne Sullivan Macy.
Care of the Neonate with Prenatal Opioid Exposure – Advanced Practice
Medication Assisted Treatment and Pregnancy
Substance Exposed Newborns: Addressing Substance Use Disorder
Screening and Referral
Neonatal Abstinence Syndrome: An emerging issue for Part C systems?
High Risk neonatal nursing
Drug Use During Pregnancy:
Medication Assisted Treatment and Pregnancy
Addressing Infant Mental Health in Maternal Mental Illness
Neonatal Abstinence Syndrome
Significance to Nursing
Demographics.
BoRN ADDICTED: Neonatal Abstinence syndrome
W.H.O. DEFINITION OF PRIMARY CARE
NEONATAL ABSTINENCE SYNDROME
Mommies Program – Outpatient Treatment NAS Residential Treatment
Treating and Managing Opioid Use Disorder in Pregnancy
Dr. Sarah Fernandez PGY4 NOSM, Pediatrics, Thunder Bay Campus
Presentation transcript:

Anne Merewood PhD MPH IBCLC Associate Professor of Pediatrics, Boston University School of Medicine Consultant to the Rocky Mountain Tribal Leaders Council

A growing problem across the US; health care workers struggling to meet the challenges On some reservations, the problem is overwhelming in both hospital and community No easy answers but raising awareness is critical Illicit drug use in adolescents and pregnant women

Illicit substance use around the time of birth: Broader implications Not just a “maternal” problem Domestic violence Suicide

Illicit substance use around the time of birth: Broader implications Child neglect/abuse Multiple drug use; alcohol use Law enforcement and custody issues Financial issues; poverty; hunger Medical issues – Hepatitis C; HIV; mental health, etc

Illicit substance use around the time of birth Ongoing ‘tension’ of personal ‘stance’… A moral issue? A medical issue? Emotional and complex when infants/young children are involved Even more complex among health care professionals who may have been exposed to the same issues

Illicit substance use around the time of birth Beliefs of health care workers may impact how they react; lead to conflict Policies are critical to ensure consistent treatment Health care workers often from the same community – pressures, confidentiality? Burnout/compassion fatigue among health care professionals

Illicit substance use around the time of birth Small communities with complex relationships Some clinicians experience pressure from patients (“we need opiates”) which conflicts with current work to reduce iatrogenic- induced opiate dependency

Prevalence of illicit drug use in the US Illicit drug use SAMHSA: Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-48, HHS Publication No. (SMA) Rockville, MD

SAHMSA report (2013) 9.4% of the US population over 12 had used illicit drugs in the month prior to the survey Marijuana was the most commonly used illicit drug (7% of population, or 80% of users used marijuana) 2 million Americans addicted to prescription opioids

Drug use by race/ethnicity Asians – 3.1% Hispanics – 8.8% Whites – 9.5% Blacks – 10.5% AI/AN – 12.3% Native Hawaiians/Pacific Islanders – 14% 2 or more races – 17.4%

Trauma increases chance of use Among women in treatment, 84% reported history of childhood sexual abuse or neglect Adolescents who had experienced physical or sexual abuse/assault 3 x more likely to report past or current substance abuse >70% adolescents receiving treatment for substance abuse reported a history of trauma exposure Frederick S. Cohen and Judianne Densen- Gerber J.D., M.D Funk RR, McDermeit M, Godley SH, Adams L. Child Maltreat 2003 National Survey of Adolescents 2003

SAHMSA data: 2013

Drug Availability: Prescription Opioid Statistics in US

Drug use in pregnancy 5% illicit drug use overall 11% rate in same group, not pregnant 15% among pregnant year olds 9% among pregnant year olds 3% among pregnant year olds

 5.6 infants/1,000 births, nationally  9/1000 in Montana  30%+ on some MT reservations Opioid use in pregnancy

Treatment for pregnant women who use opioids Maintenance therapy: ACOG’s standard of care Methadone or buprenorphine commonly prescribed, backed by testing and counseling Goal: Dose just high enough to stop use and block cravings Dose may need adjustment during pregnancy Dose unrelated to severity of infant withdrawal

Positives of opioid maintenance For pregnant woman: Prevents detox/relapse cycle Reduces illicit drug use and related complications For the fetus/baby: Prevents in utero opioid peaks/depressions Decreases preterm delivery and IUGR Decreases morbidity/ mortality Still likely to suffer NAS (Neonatal Abstinence Syndrome)

Neonatal Abstinence Syndrome (NAS) An infant with NAS suffers from ‘withdrawal’ symptoms resulting from maternal opioid use in pregnancy NAS affects 60-80% of exposed infants 20% of NAS babies in MT are low birthweight (compared to 9% in non NAS) $53,000 per infant; 80% Medicaid patients

Increase in NAS 2000 to 2012 saw a 5-fold increase in the proportion of US babies born with NAS In 2012, 21,732 US infants born with NAS – 1 every 25 minutes statistics/infographics/dramatic-increases-in-maternal-opioid-use-neonatal- abstinence-syndrome

Typically hours after birth but can surface as late as 7 days after birth 60-70% require medication treatment – standard of care is morphine Inability to predict/not dose related Inpatient monitoring period of at least 5 days NAS

SystemSymptoms Central Nervous System Tremors Irritability Sleep disturbance High pitched crying Hypertonia Hyperactive reflexes Myoclonic Jerks Generalized convulsions NAS Slide credit: Elisha Wachman, MD, Boston Medical Center

SystemSymptoms Gastrointestinal System Poor feeding Vomiting Diarrhea Excessive sucking Respiratory System Tachypnea Apnea Respiratory distress Slide credit: Elisha Wachman, MD, Boston Medical Center

System Symptoms Autonomic Nervous System Sneezing Nasal stuffiness Yawning Mottling Fever Sweating Slide credit: Elisha Wachman, MD, Boston Medical Center

Central Nervous System Disturbances Metabolic, Vasomotor, and Respiratory Disturbance Gastrointestinal Disturbance Excessive High Pitched Crying – 2 Continuous High Pitched Crying - 3 Sweating – 1Excessive Sucking – 1 Sleep < 1 Hr After Feeding – 3 Sleep < 2 Hr After Feeding – 2 Sleep < 3 Hr After Feeding – 1 Fever < 101 (37.2 – 38.3 C) – 1 Fever > 101 (38.4 C) – 2 Poor feeding – 2 Hyperactive Moro Reflex – 2 Markedly Hyperactive Moro Reflex – 3 Frequent Yawning (>3) – 1Regurgitation – 2 Projective Vomiting – 3 Mild Tremors Disturbed – 1 Mod – Severe Tremors Disturbed – 2 Mottling – 1Loose Stools – 2 Watery Stools – 3 Mild Tremors Undisturbed – 3 Mod – Severe Tremors Undisturbed - 4 Nasal Stuffiness – 1 Increased Muscle Tone - 2Sneezing (>3) – 1 Excoriation – 1Nasal Flaring – 2 Myoclonic Jerk – 3Respiratory Rate (>60) – 1 Respiratory Rate (>60 with Retractions) – 2 Seizures – 5 Finnegan’s scoring tool

Protective/ameliorating factors Breastfeeding Skin to skin care Maternal stability and presence at the bedside Low light/stimulation Prematurity

Breastfeeding and illicit substance use Breastfeeding and illicit substance use All IHS OB facilities gained Baby-Friendly™ designation by 12/2014 “Baby-Friendly” is a WHO initiative which promotes breastfeeding and optimal MCH practices in the hospital Many IHS OB hospitals have high breastfeeding rates During the IHS Baby-Friendly initiative, the question arose – how to handle breastfeeding and illicit substance use

A complex context Many AI/AN women live in settings where breastfeeding is the norm and rates are high ‘Policing’ breastfeeding is unrealistic Not breastfeeding adds to health risks Stories emerge about women breastfeeding on drugs and infants dying So what do we advise?

“Despite the myriad factors that may make breastfeeding a difficult choice for women with substance use disorders, drug-exposed infants, who are at a high risk for an array of medical, psychological, and developmental issues, as well as their mothers, stand to benefit significantly from breastfeeding.” Academy of Breastfeeding Medicine Clinical Protocol #21: Guidelines for Breastfeeding and Substance Use or Substance Use Disorder, Revised 2015

Where can I get a “definitive” answer? There are no definitive answers, but LactMed is an excellent source of information htm LactMed is a service of the NIH and it updates with new evidence as it comes in

In conclusion…. Illicit drug use/opioid use in the perinatal period is a complex and growing problem There are effective treatments but these are not always made available in Indian Country Education is key to assessing options This webinar skimmed the surface – questions and suggestions for additional information?